Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for REC-3565 in R/R B-cell Lymphoma. The expected timing is based on the latest available company guidance and may change.
EXCELERIZE study. 4/8/25- First patient dosed in Ph1. 5/5/25- Early Ph1 PK & safety data in H2 2026. 11/05/25:- Early Ph1 monotherapy safety and PK data timing updated to H1 2027. 02/25/26:- Early Ph1 monotherapy safety and PK data remain expected in H1 2027. 05/06/26:- Early Ph1 monotherapy safety and PK data reiterated for H1 2027. 08/05/26:- Early Ph1 monotherapy safety and PK data reiterated for H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.